Sani H. Kizilbash

Oct 31, 2024 | jamanetwork.com | Jann N. Sarkaria |Karla V. Ballman |Sani H. Kizilbash

Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial Key PointsQuestion  Does the polyadenosine diphosphate-ribose polymerase (PARP) inhibitor veliparib enhance the efficacy of temozolomide in patients with newly diagnosed, MGMT promoter hypermethylated glioblastoma?

Aug 1, 2023 | thejns.org | Sukwoo Hong |John Atkinson |Dana Erickson |Sani H. Kizilbash

Contributor Notes Correspondence Jamie J. Van Gompel: Mayo Clinic, Rochester, MN. [email protected]. DOI: 10.3171/2023.5.FOCUS23185. Dr. Kizilbash reported grants from Orbus Therapeutics, Apollomics, Wayshine Biopharma, Celgene, LOXO Oncology, Incyte, Nerviano Medical Sciences, Hutchinson Medipharma, and CNS Pharmaceuticals outside the submitted work.